Glaucoma Clinical Trial
Official title:
Randomized Controlled Trial of Lucentis in the Management of New Onset Neovascular Glaucoma
Neovascular glaucoma is a potentially debilitating disease of the eye. Vascular eye disease such as diabetes and vein occlusions can cause the retina to release factors that promote the growth of abnormal blood vessels. These abnormal vessels can grow in the drainage mechanism of the eye causing pressure in the eye to markedly increase. This can potentially cause irreversible damage to the optic nerve from glaucoma leading to permanent blindness and painful eyes. Conventional treatments including laser and freezing therapy take weeks to cause regression in abnormal blood vessel growth. This delay often results in permanent vision loss and pain. New medications targeted at more immediately reducing blood vessel growth may aid in the treatment of this disease.
Hypothesis:
Intravitreal injection of Lucentis prior to conventional treatment for neovascular glaucoma
improves overall outcome compared to conventional treatment alone.
Specific Aims:
To determine if pre-treatment with a single intravitreal injection of Lucentis prior to
conventional treatment prevents severe vision loss and improves intraocular pressure control
compared to conventional treatment alone.
Neovascular glaucoma is a potentially devastating consequence of fibrovascular proliferation
of the anterior chamber angle with subsequent obstruction of the trabecular meshwork. The
production of peripheral anterior synechiae along the trabecular meshwork leads to
progressive angle closure. The subsequent elevation in intraocular pressure is difficult to
manage, often leading to rapid progression of glaucoma and significant loss of vision.
Enucleation for blind, painful eyes secondary to neovascular glaucoma is not an uncommon
sequelae.
Neovascular glaucoma has many etiologic causes, the vast majority resulting from retinal
ischemia secondary to relatively common diseases such as central retinal vein occlusion,
proliferative diabetic retinopathy and ocular ischemic syndrome (carotid stenosis).
(Sivac-Callcott et al., 2001) Vascular endothelial growth factor is likely a major
contributor to the development of angle and iris neovascularization. (Ferrara, 2004) Although
panretinal photocoagulation and/or cryoablation are mainstays of conventional treatment for
neovascular glaucoma, the delayed therapeutic effect of these interventions often results in
the formation of peripheral anterior synechiae and permanent angle closure.
Recent limited case series have demonstrated a role for bevacizumab (Avastin) in reducing
rubeosis iridis and as an adjunct for neovascular glaucoma. (Grisanti et al., 2006; Davidorf
et al., 2006; Iliev et al., 2006; Kahook, Schuman, Noecker, 2006) However, no prospective
studies have examined the potential utility of anti-vascular endothelial growth factor agents
in the treatment of neovascular glaucoma. Intravitreal Lucentis is the standard of care for
the treatment of exudative macular degeneration. Pharmacologic agents such as Lucentis, which
selectively inhibit vascular endothelial growth factor may provide an important therapeutic
adjunct for the treatment of neovascular glaucoma by more immediately causing regression of
angle neovascularization and thereby providing a window for permanent treatment with laser or
cryotherapy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A |